

**MAP4K1 / HPK1 Antibody (N-Terminus)**  
**Goat Polyclonal Antibody**  
**Catalog # ALS14553****Specification**

---

**MAP4K1 / HPK1 Antibody (N-Terminus) - Product Information**

Application	IHC
Primary Accession	<a href="#">O92918</a>
Reactivity	Human
Host	Goat
Clonality	Polyclonal
Calculated MW	91kDa KDa

**MAP4K1 / HPK1 Antibody (N-Terminus) - Additional Information****Gene ID** 11184**Other Names**

Mitogen-activated protein kinase kinase kinase kinase 1, 2.7.11.1, Hematopoietic progenitor kinase, MAPK/ERK kinase kinase kinase 1, MEK kinase kinase 1, MEKKK 1, MAP4K1, HPK1

**Target/Specificity**

Human MAP4K1. This antibody is expected to recognise isoform 1 (NP\_001036065.1) and isoform 2 (NP\_009112.1).

**Reconstitution & Storage**

Store at -20°C. Minimize freezing and thawing.

**Precautions**

MAP4K1 / HPK1 Antibody (N-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

**MAP4K1 / HPK1 Antibody (N-Terminus) - Protein Information****Name** MAP4K1 ([HGNC:6863](#))**Synonyms** HPK1**Function**

Serine/threonine-protein kinase, which plays a role in the response to environmental stress (PubMed:<a href="http://www.uniprot.org/citations/24362026" target="\_blank">24362026</a>). Appears to act upstream of the JUN N-terminal pathway (PubMed:<a href="http://www.uniprot.org/citations/8824585" target="\_blank">8824585</a>). Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:<a href="http://www.uniprot.org/citations/26437443" target="\_blank">26437443</a>). May play a

role in hematopoietic lineage decisions and growth regulation (PubMed:<a href="http://www.uniprot.org/citations/24362026" target="\_blank">24362026</a>, PubMed:<a href="http://www.uniprot.org/citations/8824585" target="\_blank">8824585</a>). Together with CLNK, it enhances CD3-triggered activation of T-cells and subsequent IL2 production (By similarity).

#### **Tissue Location**


Expressed primarily in hematopoietic organs, including bone marrow, spleen and thymus. Also expressed at very low levels in lung, kidney, mammary glands and small intestine

#### **MAP4K1 / HPK1 Antibody (N-Terminus) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### **MAP4K1 / HPK1 Antibody (N-Terminus) - Images**



Anti-MAP4K1 antibody IHC of human thymus.

#### **MAP4K1 / HPK1 Antibody (N-Terminus) - Background**

Serine/threonine-protein kinase, which may play a role in the response to environmental stress. Appears to act upstream of the JUN N-terminal pathway. May play a role in hematopoietic lineage decisions and growth regulation. Able to autophosphorylate.

#### **MAP4K1 / HPK1 Antibody (N-Terminus) - References**

Hu M.C.-T., et al. *Genes Dev.* 10:2251-2264(1996).  
Grimwood J., et al. *Nature* 428:529-535(2004).  
Oppermann F.S., et al. *Mol. Cell. Proteomics* 8:1751-1764(2009).  
Mayya V., et al. *Sci. Signal.* 2:RA46-RA46(2009).  
Burkard T.R., et al. *BMC Syst. Biol.* 5:17-17(2011).